ZA200510453B - Dual NK 1/NK 3 antagonists for treating schizophrenia - Google Patents
Dual NK 1/NK 3 antagonists for treating schizophrenia Download PDFInfo
- Publication number
- ZA200510453B ZA200510453B ZA200510453A ZA200510453A ZA200510453B ZA 200510453 B ZA200510453 B ZA 200510453B ZA 200510453 A ZA200510453 A ZA 200510453A ZA 200510453 A ZA200510453 A ZA 200510453A ZA 200510453 B ZA200510453 B ZA 200510453B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- methyl
- isobutyramide
- pyridin
- bis
- Prior art date
Links
- 201000000980 schizophrenia Diseases 0.000 title claims description 25
- 230000009977 dual effect Effects 0.000 title claims description 4
- 239000005557 antagonist Substances 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 164
- 150000001875 compounds Chemical class 0.000 claims description 131
- 229910052736 halogen Inorganic materials 0.000 claims description 67
- 150000002367 halogens Chemical class 0.000 claims description 67
- 229910052739 hydrogen Inorganic materials 0.000 claims description 62
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 57
- 125000001424 substituent group Chemical group 0.000 claims description 47
- -1 3,5-bis-trifluoromethyl-phenyl Chemical group 0.000 claims description 39
- 125000003545 alkoxy group Chemical group 0.000 claims description 34
- 150000002431 hydrogen Chemical class 0.000 claims description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 14
- 208000024891 symptom Diseases 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 239000002464 receptor antagonist Substances 0.000 claims description 7
- 229940044551 receptor antagonist Drugs 0.000 claims description 7
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 claims description 6
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 6
- 102100029409 Neuromedin-K receptor Human genes 0.000 claims description 6
- 229940047889 isobutyramide Drugs 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- RYIJZMRGOFTVRF-JOCHJYFZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(3r)-3-(hydroxymethyl)morpholin-4-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](COCC2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RYIJZMRGOFTVRF-JOCHJYFZSA-N 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- VNHFNQAUCBUFFZ-UHFFFAOYSA-N n-[6-[bis(2-hydroxyethyl)amino]-4-(2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N(CCO)CCO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VNHFNQAUCBUFFZ-UHFFFAOYSA-N 0.000 claims description 3
- IODSNPBPMHUOAV-FQEVSTJZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-bromophenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC=CC=2)Br)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IODSNPBPMHUOAV-FQEVSTJZSA-N 0.000 claims description 2
- PJNZCNXVMIBQMX-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-(1,3-dihydroxypropan-2-ylamino)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NC(CO)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PJNZCNXVMIBQMX-UHFFFAOYSA-N 0.000 claims description 2
- FFNHZYKLPUJECT-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-(2,3-dihydroxypropylamino)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NCC(O)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FFNHZYKLPUJECT-UHFFFAOYSA-N 0.000 claims description 2
- MQMVZXGQVFMBSD-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-(2-hydroxybutylamino)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(NCC(O)CC)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MQMVZXGQVFMBSD-UHFFFAOYSA-N 0.000 claims description 2
- VTQWIZKUIUWSFO-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-(2-hydroxypropylamino)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(NCC(O)C)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VTQWIZKUIUWSFO-UHFFFAOYSA-N 0.000 claims description 2
- VZJXTFSCMKJPJF-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(2-hydroxy-2-methylpropyl)amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NCC(C)(C)O)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VZJXTFSCMKJPJF-UHFFFAOYSA-N 0.000 claims description 2
- ZNBNHJFCUVHQJE-OAHLLOKOSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[[(2r)-1-hydroxypropan-2-yl]amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N[C@@H](CO)C)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZNBNHJFCUVHQJE-OAHLLOKOSA-N 0.000 claims description 2
- FEFTXAMKVOVPQS-IVZQSRNASA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[[(2r,3r)-1,3-dihydroxybutan-2-yl]amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N[C@H](CO)[C@H](O)C)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FEFTXAMKVOVPQS-IVZQSRNASA-N 0.000 claims description 2
- QKUWXKYOFPEMTA-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[2-hydroxyethyl(3-hydroxypropyl)amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N(CCO)CCCO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QKUWXKYOFPEMTA-UHFFFAOYSA-N 0.000 claims description 2
- KTEWWRXIKIYSJT-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluorophenyl)-6-[2-hydroxyethyl(methyl)amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)(C)C(=O)N(C)C=1C=NC(N(CCO)C)=CC=1C1=CC=C(F)C=C1 KTEWWRXIKIYSJT-UHFFFAOYSA-N 0.000 claims description 2
- JITYQNYMCYXZHJ-RPBOFIJWSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(5-fluoro-2-methylphenyl)-6-[(2r,3s)-3-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H]([C@@H](O)CC2)CO)C=C(C=2C(=CC=C(F)C=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JITYQNYMCYXZHJ-RPBOFIJWSA-N 0.000 claims description 2
- UPARBIBJADLUBJ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NC(CO)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UPARBIBJADLUBJ-UHFFFAOYSA-N 0.000 claims description 2
- JQAZEIANSCODNU-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[2-hydroxyethyl(propyl)amino]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CCO)CCC)=CC(C=2C(=CC=CC=2)C)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JQAZEIANSCODNU-UHFFFAOYSA-N 0.000 claims description 2
- LOIZQROBGQMEQD-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[butyl(2-hydroxyethyl)amino]-4-(2-chlorophenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CCO)CCCC)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LOIZQROBGQMEQD-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- YKGGDVAVJGYZBU-UHFFFAOYSA-N n-[4-(2-chlorophenyl)-6-(2-hydroxyethylamino)pyridin-3-yl]-2-(3,5-dichlorophenyl)-n,2-dimethylpropanamide Chemical compound C=1N=C(NCCO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(Cl)=CC(Cl)=C1 YKGGDVAVJGYZBU-UHFFFAOYSA-N 0.000 claims description 2
- QUBPXXSBEOEBLO-UHFFFAOYSA-N n-[6-[bis(2-hydroxyethyl)amino]-4-(3,4-dichlorophenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N(CCO)CCO)C=C(C=2C=C(Cl)C(Cl)=CC=2)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QUBPXXSBEOEBLO-UHFFFAOYSA-N 0.000 claims description 2
- UNOHXCABJFINAY-UHFFFAOYSA-N n-[6-[bis(2-hydroxyethyl)amino]-4-(5-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N(CCO)CCO)C=C(C=2C(=CC=C(F)C=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UNOHXCABJFINAY-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 5
- DLXWHNAASNNCOO-QFIPXVFZSA-N 2-(3,5-dimethoxyphenyl)-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound COC1=CC(OC)=CC(C(C)(C)C(=O)N(C)C=2C(=CC(=NC=2)N2[C@@H](CCC2)CO)C=2C(=CC(F)=CC=2)C)=C1 DLXWHNAASNNCOO-QFIPXVFZSA-N 0.000 claims 3
- HJBWGSWOUFHYHY-QFIPXVFZSA-N 2-(3,5-dimethoxyphenyl)-n-[6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound COC1=CC(OC)=CC(C(C)(C)C(=O)N(C)C=2C(=CC(=NC=2)N2[C@@H](CCC2)CO)C=2C(=CC=CC=2)C)=C1 HJBWGSWOUFHYHY-QFIPXVFZSA-N 0.000 claims 3
- WJYMMVSCRSWDKB-UHFFFAOYSA-N 2-[3,5-bis(difluoromethoxy)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-piperazin-1-ylpyridin-3-yl]propanamide Chemical compound C=1N=C(N2CCNCC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(OC(F)F)=CC(OC(F)F)=C1 WJYMMVSCRSWDKB-UHFFFAOYSA-N 0.000 claims 3
- IFZVNRXXYCMABI-FQEVSTJZSA-N 2-[3,5-bis(difluoromethoxy)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(OC(F)F)=CC(OC(F)F)=C1 IFZVNRXXYCMABI-FQEVSTJZSA-N 0.000 claims 3
- PMCPVUYIELSIPH-FCHUYYIVSA-N 2-(3,5-dimethoxyphenyl)-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound COC1=CC(OC)=CC(C(C)(C)C(=O)N(C)C=2C(=CC(=NC=2)N2[C@@H](C[C@@H](O)C2)CO)C=2C(=CC(F)=CC=2)C)=C1 PMCPVUYIELSIPH-FCHUYYIVSA-N 0.000 claims 2
- VRRNSUBPXWRJSR-SFHVURJKSA-N 2-[3,5-bis(difluoromethoxy)phenyl]-n-[4-(2-chlorophenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(OC(F)F)=CC(OC(F)F)=C1 VRRNSUBPXWRJSR-SFHVURJKSA-N 0.000 claims 2
- GEZVXGVXHYIGQY-UHFFFAOYSA-N 2-[3,5-bis(difluoromethoxy)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-(4-methylsulfonylpiperazin-1-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCN(CC2)S(C)(=O)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(OC(F)F)=CC(OC(F)F)=C1 GEZVXGVXHYIGQY-UHFFFAOYSA-N 0.000 claims 2
- XHAOKNGJCJWQNU-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-(4-methylsulfonylpiperazin-1-yl)pyridin-3-yl]propanamide Chemical compound C=1N=C(N2CCN(CC2)S(C)(=O)=O)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XHAOKNGJCJWQNU-UHFFFAOYSA-N 0.000 claims 2
- NTYHGSNZZDYQIT-RPWUZVMVSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-bromophenyl)-6-[(2r,3s)-3-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H]([C@@H](O)CC2)CO)C=C(C=2C(=CC=CC=2)Br)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NTYHGSNZZDYQIT-RPWUZVMVSA-N 0.000 claims 2
- CTGJMYZZXHECAG-GOSISDBHSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(2r)-2-methyl-4-methylsulfonylpiperazin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C[C@@H]1CN(S(C)(=O)=O)CCN1C1=CC(C=2C(=CC=CC=2)Cl)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 CTGJMYZZXHECAG-GOSISDBHSA-N 0.000 claims 2
- XDFFVHQCALIXPH-FQEVSTJZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XDFFVHQCALIXPH-FQEVSTJZSA-N 0.000 claims 2
- GYLUNZXAMUSUGX-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[2-(methylsulfamoyl)ethylamino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(NCCS(=O)(=O)NC)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GYLUNZXAMUSUGX-UHFFFAOYSA-N 0.000 claims 2
- SRADRAYPRNPPHJ-RPBOFIJWSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(3-fluoro-2-methylphenyl)-6-[(2r,3s)-3-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H]([C@@H](O)CC2)CO)C=C(C=2C(=C(F)C=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SRADRAYPRNPPHJ-RPBOFIJWSA-N 0.000 claims 2
- NPDQCWRHYKGKIH-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-(1-oxa-4-thia-8-azaspiro[4.5]decan-8-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCC3(CC2)SCCO3)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NPDQCWRHYKGKIH-UHFFFAOYSA-N 0.000 claims 2
- ACPKHOFTORRRHF-NRFANRHFSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-2-(hydroxymethyl)-4-oxopyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CC(=O)C2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ACPKHOFTORRRHF-NRFANRHFSA-N 0.000 claims 2
- BZNLSZSNUJNHIK-IBGZPJMESA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-2-methyl-4-methylsulfonylpiperazin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C[C@H]1CN(S(C)(=O)=O)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 BZNLSZSNUJNHIK-IBGZPJMESA-N 0.000 claims 2
- KIWPQCODGUAEAZ-LJQANCHMSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(3r)-3-methyl-4-methylsulfonylpiperazin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1CN(S(C)(=O)=O)[C@H](C)CN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 KIWPQCODGUAEAZ-LJQANCHMSA-N 0.000 claims 2
- AURSBCCZLJUEMY-QHCPKHFHSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(3s)-3-(hydroxymethyl)-4-methylsulfonylpiperazin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@@H](CO)N(CC2)S(C)(=O)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 AURSBCCZLJUEMY-QHCPKHFHSA-N 0.000 claims 2
- KIWPQCODGUAEAZ-IBGZPJMESA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(3s)-3-methyl-4-methylsulfonylpiperazin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1CN(S(C)(=O)=O)[C@@H](C)CN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 KIWPQCODGUAEAZ-IBGZPJMESA-N 0.000 claims 2
- WHTUGSAQJVBVIW-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[3-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(CO)CC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WHTUGSAQJVBVIW-UHFFFAOYSA-N 0.000 claims 2
- UAMQJKMLSMBOCS-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[4-(hydroxymethyl)-1,3-oxazolidin-3-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C(COC2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UAMQJKMLSMBOCS-UHFFFAOYSA-N 0.000 claims 2
- DUARDUGBMBWIEQ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-(3,3-dimethyl-4-methylsulfonylpiperazin-1-yl)-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(C)(C)N(CC2)S(C)(=O)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DUARDUGBMBWIEQ-UHFFFAOYSA-N 0.000 claims 2
- UZVLOPCFBQIPRR-VWLOTQADSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(2s)-4-(cyclopropanecarbonyl)-2-(hydroxymethyl)piperazin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CN(CC2)C(=O)C2CC2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UZVLOPCFBQIPRR-VWLOTQADSA-N 0.000 claims 2
- YFLJFGCJMKTJGA-HSZRJFAPSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(3r)-3-(hydroxymethyl)-4-methylsulfonylpiperazin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@H](CO)N(CC2)S(C)(=O)=O)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YFLJFGCJMKTJGA-HSZRJFAPSA-N 0.000 claims 2
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims 2
- IIDDGKOXLAHZFV-VQTJNVASSA-N n-[4-(2-chlorophenyl)-6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(F)=CC(C(F)(F)F)=C1 IIDDGKOXLAHZFV-VQTJNVASSA-N 0.000 claims 2
- ORLAIHRQEMSLST-QFIPXVFZSA-N n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(F)=CC(C(F)(F)F)=C1 ORLAIHRQEMSLST-QFIPXVFZSA-N 0.000 claims 2
- NCVMNDPUEFVZKI-UHFFFAOYSA-N n-[6-(2-aminoethylamino)-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NCCN)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NCVMNDPUEFVZKI-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- JDEUUKYNTHHAQH-UHFFFAOYSA-N 2,2-dimethylbutanamide Chemical compound CCC(C)(C)C(N)=O JDEUUKYNTHHAQH-UHFFFAOYSA-N 0.000 claims 1
- FLQQTHKKINVDIU-UHFFFAOYSA-N 2-(3,5-dichlorophenyl)-n-[4-(4-fluoro-2-methylphenyl)-6-(2-hydroxyethylamino)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NCCO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(Cl)=CC(Cl)=C1 FLQQTHKKINVDIU-UHFFFAOYSA-N 0.000 claims 1
- MECPEGMUGNEABG-FCHUYYIVSA-N 2-(3,5-difluorophenyl)-n-[6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(F)=CC(F)=C1 MECPEGMUGNEABG-FCHUYYIVSA-N 0.000 claims 1
- OKFSQMIRWPMRSE-QFIPXVFZSA-N 2-(3-chloro-5-methoxyphenyl)-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound COC1=CC(Cl)=CC(C(C)(C)C(=O)N(C)C=2C(=CC(=NC=2)N2[C@@H](CCC2)CO)C=2C(=CC(F)=CC=2)C)=C1 OKFSQMIRWPMRSE-QFIPXVFZSA-N 0.000 claims 1
- USYOOSMOYIXPOK-UHFFFAOYSA-N 2-[3,5-bis(difluoromethoxy)phenyl]-n-[4-(2-chlorophenyl)-6-(4-methylsulfonylpiperazin-1-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCN(CC2)S(C)(=O)=O)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(OC(F)F)=CC(OC(F)F)=C1 USYOOSMOYIXPOK-UHFFFAOYSA-N 0.000 claims 1
- ASZYNACSIPAQKC-UHFFFAOYSA-N 2-[3,5-bis(difluoromethoxy)phenyl]-n-[4-(2-chlorophenyl)-6-piperazin-1-ylpyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCNCC2)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(OC(F)F)=CC(OC(F)F)=C1 ASZYNACSIPAQKC-UHFFFAOYSA-N 0.000 claims 1
- QVDTYJUSLCAUNO-UHFFFAOYSA-N 2-[3,5-bis(difluoromethoxy)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-piperazin-1-ylpyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCNCC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(OC(F)F)=CC(OC(F)F)=C1 QVDTYJUSLCAUNO-UHFFFAOYSA-N 0.000 claims 1
- GZJUAJSAZCNUDO-UHFFFAOYSA-N 2-[3,5-bis(difluoromethoxy)phenyl]-n-[6-(2-hydroxyethylamino)-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NCCO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(OC(F)F)=CC(OC(F)F)=C1 GZJUAJSAZCNUDO-UHFFFAOYSA-N 0.000 claims 1
- YVTVTEVWQMXZBV-FQEVSTJZSA-N 2-[3,5-bis(difluoromethoxy)phenyl]-n-[6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(OC(F)F)=CC(OC(F)F)=C1 YVTVTEVWQMXZBV-FQEVSTJZSA-N 0.000 claims 1
- HSZOFONMTKWVOA-VQTJNVASSA-N 2-[3,5-bis(difluoromethoxy)phenyl]-n-[6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(OC(F)F)=CC(OC(F)F)=C1 HSZOFONMTKWVOA-VQTJNVASSA-N 0.000 claims 1
- HOCYHCXFFVTSJK-IBGZPJMESA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2,3-dichlorophenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=C(Cl)C=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HOCYHCXFFVTSJK-IBGZPJMESA-N 0.000 claims 1
- GFZLBFNLJYDIKU-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2,4-dichlorophenyl)-6-(2-hydroxyethylamino)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NCCO)C=C(C=2C(=CC(Cl)=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GFZLBFNLJYDIKU-UHFFFAOYSA-N 0.000 claims 1
- SDCQWSQMDMPXOU-AWEZNQCLSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2,4-dichlorophenyl)-6-[[(2s)-2-hydroxypropyl]amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(NC[C@@H](O)C)=CC(C=2C(=CC(Cl)=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SDCQWSQMDMPXOU-AWEZNQCLSA-N 0.000 claims 1
- UNFCURZHGVNCPJ-RPWUZVMVSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chloro-4-fluorophenyl)-6-[(2r,3s)-3-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H]([C@@H](O)CC2)CO)C=C(C=2C(=CC(F)=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UNFCURZHGVNCPJ-RPWUZVMVSA-N 0.000 claims 1
- NMJJNLDOUBLQBI-PMACEKPBSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chloro-4-fluorophenyl)-6-[(2s,4s)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@H](O)C2)CO)C=C(C=2C(=CC(F)=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NMJJNLDOUBLQBI-PMACEKPBSA-N 0.000 claims 1
- OSEJTQWCDDUCGE-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-(2-methylsulfonylethylamino)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NCCS(C)(=O)=O)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OSEJTQWCDDUCGE-UHFFFAOYSA-N 0.000 claims 1
- JITHLUVUJPKZKC-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-(3-methylsulfonylpyrrolidin-1-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(CC2)S(C)(=O)=O)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JITHLUVUJPKZKC-UHFFFAOYSA-N 0.000 claims 1
- TUZJHBYVSPEXHW-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-(4-hydroxypiperidin-1-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCC(O)CC2)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 TUZJHBYVSPEXHW-UHFFFAOYSA-N 0.000 claims 1
- WIYNLHLAIYZFQQ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-(4-methylsulfonylpiperidin-1-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCC(CC2)S(C)(=O)=O)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WIYNLHLAIYZFQQ-UHFFFAOYSA-N 0.000 claims 1
- OFXGPUCSXYQAEH-OAQYLSRUSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(2r)-2-(hydroxymethyl)piperidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@H](CCCC2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OFXGPUCSXYQAEH-OAQYLSRUSA-N 0.000 claims 1
- HATNRBQJMSRMEP-RPWUZVMVSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(2r,3s)-3-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H]([C@@H](O)CC2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HATNRBQJMSRMEP-RPWUZVMVSA-N 0.000 claims 1
- CJTUMEIDUUCTSL-UXHICEINSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(2r,4s)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@H](C[C@H](O)C2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CJTUMEIDUUCTSL-UXHICEINSA-N 0.000 claims 1
- CYDMWSSMUBQXRD-LJQANCHMSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(3r)-3-hydroxypyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@H](O)CC2)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CYDMWSSMUBQXRD-LJQANCHMSA-N 0.000 claims 1
- BHTGMWPVYJFLEQ-NRFANRHFSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1[C@@H](N(C)C)CCN1C1=CC(C=2C(=CC=CC=2)Cl)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 BHTGMWPVYJFLEQ-NRFANRHFSA-N 0.000 claims 1
- CYDMWSSMUBQXRD-IBGZPJMESA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(3s)-3-hydroxypyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@@H](O)CC2)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CYDMWSSMUBQXRD-IBGZPJMESA-N 0.000 claims 1
- FBEIDIBLKITGHL-SFHVURJKSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(3s)-3-methyl-4-methylsulfonylpiperazin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1CN(S(C)(=O)=O)[C@@H](C)CN1C1=CC(C=2C(=CC=CC=2)Cl)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 FBEIDIBLKITGHL-SFHVURJKSA-N 0.000 claims 1
- PWBOYEFTCGHFBB-ZRZAMGCNSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(3s,4r)-3,4-dihydroxypyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@@H](O)[C@@H](O)C2)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PWBOYEFTCGHFBB-ZRZAMGCNSA-N 0.000 claims 1
- OFXGPUCSXYQAEH-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[2-(hydroxymethyl)piperidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C(CCCC2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OFXGPUCSXYQAEH-UHFFFAOYSA-N 0.000 claims 1
- AEGNZBVDAJJKQJ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[2-hydroxyethyl(3-hydroxypropyl)amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N(CCO)CCCO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 AEGNZBVDAJJKQJ-UHFFFAOYSA-N 0.000 claims 1
- HGZMZNGGJOZVFE-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[2-hydroxyethyl(methyl)amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CCO)C)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HGZMZNGGJOZVFE-UHFFFAOYSA-N 0.000 claims 1
- CGBUNDZAPUCEFL-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[2-hydroxyethyl(pentyl)amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CCO)CCCCC)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CGBUNDZAPUCEFL-UHFFFAOYSA-N 0.000 claims 1
- VPPFVSVLCATXPY-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[2-hydroxyethyl(propyl)amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CCO)CCC)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VPPFVSVLCATXPY-UHFFFAOYSA-N 0.000 claims 1
- NAWYIOWWDNCGCO-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[3-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(CO)CC2)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NAWYIOWWDNCGCO-UHFFFAOYSA-N 0.000 claims 1
- XWYQKVWFSXAUTM-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[3-hydroxy-2-(hydroxymethyl)piperidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C(C(O)CCC2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XWYQKVWFSXAUTM-UHFFFAOYSA-N 0.000 claims 1
- DVUJMQCPKOSVAS-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[4-hydroxy-3-(hydroxymethyl)piperidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(CO)C(O)CC2)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DVUJMQCPKOSVAS-UHFFFAOYSA-N 0.000 claims 1
- BCTRWMATLIUUFO-ISKFKSNPSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[[(1r,2r)-2-hydroxycyclopentyl]amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N[C@H]2[C@@H](CCC2)O)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BCTRWMATLIUUFO-ISKFKSNPSA-N 0.000 claims 1
- VTQWIZKUIUWSFO-OAHLLOKOSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[[(2r)-2-hydroxypropyl]amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(NC[C@H](O)C)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VTQWIZKUIUWSFO-OAHLLOKOSA-N 0.000 claims 1
- ZNBNHJFCUVHQJE-HNNXBMFYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[[(2s)-1-hydroxypropan-2-yl]amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N[C@H](CO)C)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZNBNHJFCUVHQJE-HNNXBMFYSA-N 0.000 claims 1
- VTQWIZKUIUWSFO-HNNXBMFYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[[(2s)-2-hydroxypropyl]amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(NC[C@@H](O)C)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VTQWIZKUIUWSFO-HNNXBMFYSA-N 0.000 claims 1
- HQTYNIGJEVCBNU-FQEVSTJZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-fluorophenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC=CC=2)F)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HQTYNIGJEVCBNU-FQEVSTJZSA-N 0.000 claims 1
- GROSHHCEMKYRCQ-HXUWFJFHSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(3,4-dichlorophenyl)-6-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@H](CCC2)CO)C=C(C=2C=C(Cl)C(Cl)=CC=2)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GROSHHCEMKYRCQ-HXUWFJFHSA-N 0.000 claims 1
- QHIIIJCRHCPGHL-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(3-chloro-2-methylphenyl)-6-(4-methylsulfonylpiperazin-1-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCN(CC2)S(C)(=O)=O)C=C(C=2C(=C(Cl)C=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QHIIIJCRHCPGHL-UHFFFAOYSA-N 0.000 claims 1
- MUSOWXLWHXPWCT-NRFANRHFSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(3-fluoro-2-methylphenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=C(F)C=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MUSOWXLWHXPWCT-NRFANRHFSA-N 0.000 claims 1
- DKZDTMPEOPFJMO-LEWJYISDSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(3-fluoro-2-methylphenyl)-6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=C(F)C=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DKZDTMPEOPFJMO-LEWJYISDSA-N 0.000 claims 1
- KVFJHUOCXOFUPO-RPBOFIJWSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-formylphenyl)-6-[(2r,3s)-3-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H]([C@@H](O)CC2)CO)C=C(C=2C(=CC(F)=CC=2)C=O)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 KVFJHUOCXOFUPO-RPBOFIJWSA-N 0.000 claims 1
- VNYNXPNXSBTSFB-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-(1,3-thiazolidin-3-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CSCC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VNYNXPNXSBTSFB-UHFFFAOYSA-N 0.000 claims 1
- BQHBKFHUMNOVOE-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-(1-oxa-8-azaspiro[4.5]decan-8-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCC3(OCCC3)CC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BQHBKFHUMNOVOE-UHFFFAOYSA-N 0.000 claims 1
- ZRRQFCBJAVWNKZ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-(2-methylsulfanylethylamino)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(NCCSC)=CC(C=2C(=CC(F)=CC=2)C)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZRRQFCBJAVWNKZ-UHFFFAOYSA-N 0.000 claims 1
- IBIFQSLJOWBOPC-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-(2-methylsulfonylethylamino)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NCCS(C)(=O)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IBIFQSLJOWBOPC-UHFFFAOYSA-N 0.000 claims 1
- VPQACYXOBFIDPB-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-(3-methylsulfonylimidazolidin-1-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CN(CC2)S(C)(=O)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VPQACYXOBFIDPB-UHFFFAOYSA-N 0.000 claims 1
- FFQWFUQOUDHZNK-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-(3-oxopyrrolidin-1-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(=O)CC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FFQWFUQOUDHZNK-UHFFFAOYSA-N 0.000 claims 1
- LWENKLDZCHEYBQ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-(4-methylsulfonylpiperazin-1-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCN(CC2)S(C)(=O)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LWENKLDZCHEYBQ-UHFFFAOYSA-N 0.000 claims 1
- QGCVURSTBHEHHX-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-(5-oxo-1,4-diazepan-1-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCC(=O)NCC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QGCVURSTBHEHHX-UHFFFAOYSA-N 0.000 claims 1
- ZUZJRCBJXVWFFW-PSWAGMNNSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(1r,5s)-8-methylsulfonyl-3,8-diazabicyclo[3.2.1]octan-3-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C([C@]1(CC[C@@](C2)(N1S(C)(=O)=O)[H])[H])N2C(N=C1)=CC(C=2C(=CC(F)=CC=2)C)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZUZJRCBJXVWFFW-PSWAGMNNSA-N 0.000 claims 1
- YUERFHADRHAZBK-JOCHJYFZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@H](CCC2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YUERFHADRHAZBK-JOCHJYFZSA-N 0.000 claims 1
- HEDOZLKBUNKWFF-FGZHOGPDSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(2r,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HEDOZLKBUNKWFF-FGZHOGPDSA-N 0.000 claims 1
- AWPXPFYGDWXBFG-QFIPXVFZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-2-(hydroxymethyl)-2,5-dihydropyrrol-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C=CC2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 AWPXPFYGDWXBFG-QFIPXVFZSA-N 0.000 claims 1
- LIDGXLMPYMRQQO-QHCPKHFHSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-2-(hydroxymethyl)-4-methylsulfonylpiperazin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CN(CC2)S(C)(=O)=O)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LIDGXLMPYMRQQO-QHCPKHFHSA-N 0.000 claims 1
- YUERFHADRHAZBK-QFIPXVFZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YUERFHADRHAZBK-QFIPXVFZSA-N 0.000 claims 1
- RRLIZNMVEJSDSF-QHCPKHFHSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-2-(methylsulfonylmethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CS(C)(=O)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RRLIZNMVEJSDSF-QHCPKHFHSA-N 0.000 claims 1
- NVCBLRQNKZBPMH-QHCPKHFHSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s)-4-formyl-2-(hydroxymethyl)piperazin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CN(CC2)C=O)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NVCBLRQNKZBPMH-QHCPKHFHSA-N 0.000 claims 1
- AURSBCCZLJUEMY-HSZRJFAPSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(3r)-3-(hydroxymethyl)-4-methylsulfonylpiperazin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@H](CO)N(CC2)S(C)(=O)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 AURSBCCZLJUEMY-HSZRJFAPSA-N 0.000 claims 1
- RFEOVPSIVBLBSQ-HSZRJFAPSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(3r)-3-[methyl(methylsulfonyl)amino]pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1[C@H](N(C)S(C)(=O)=O)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 RFEOVPSIVBLBSQ-HSZRJFAPSA-N 0.000 claims 1
- OHLPOHAQAHQALU-QFIPXVFZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(3s)-3-(methanesulfonamido)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@H](CC2)NS(C)(=O)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OHLPOHAQAHQALU-QFIPXVFZSA-N 0.000 claims 1
- HCGIROBRNBTDFG-NRFANRHFSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[(3s)-3-hydroxypyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@@H](O)CC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HCGIROBRNBTDFG-NRFANRHFSA-N 0.000 claims 1
- VKBJIXGKPMKGCA-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[2-(methanesulfonamido)ethylamino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NCCNS(C)(=O)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VKBJIXGKPMKGCA-UHFFFAOYSA-N 0.000 claims 1
- ODWISYBAEMTIEY-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[3-(methylsulfanylmethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1C(CSC)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 ODWISYBAEMTIEY-UHFFFAOYSA-N 0.000 claims 1
- NRZZVQXORQCROE-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[3-(methylsulfinylmethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(CS(C)=O)CC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NRZZVQXORQCROE-UHFFFAOYSA-N 0.000 claims 1
- WZFJRYHSLCCXTJ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[3-(methylsulfonylmethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(CS(C)(=O)=O)CC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WZFJRYHSLCCXTJ-UHFFFAOYSA-N 0.000 claims 1
- XLZWMUZNOCMGQP-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[4-(methylsulfanylmethyl)piperidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1CC(CSC)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 XLZWMUZNOCMGQP-UHFFFAOYSA-N 0.000 claims 1
- XFHUTOWGXVTPTA-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[4-(methylsulfinylmethyl)piperidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCC(CS(C)=O)CC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XFHUTOWGXVTPTA-UHFFFAOYSA-N 0.000 claims 1
- WYXANUHEOUYIDF-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[4-[methyl(methylsulfonyl)amino]piperidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1CC(N(C)S(C)(=O)=O)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 WYXANUHEOUYIDF-UHFFFAOYSA-N 0.000 claims 1
- XXJYQSMGRIETHB-INIZCTEOSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-[[(2s)-2-hydroxypropyl]amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(NC[C@@H](O)C)=CC(C=2C(=CC(F)=CC=2)C)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XXJYQSMGRIETHB-INIZCTEOSA-N 0.000 claims 1
- VMKIZPXQGRMULH-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-fluoro-2-methylphenyl)-6-morpholin-4-ylpyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCOCC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VMKIZPXQGRMULH-UHFFFAOYSA-N 0.000 claims 1
- NTLWEVPODRFLTO-QFIPXVFZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(5-fluoro-2-methylphenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC=C(F)C=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NTLWEVPODRFLTO-QFIPXVFZSA-N 0.000 claims 1
- NUWXTOULZJWJQP-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-(3,3-dimethyl-4-methylsulfonylpiperazin-1-yl)-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(C)(C)N(CC2)S(C)(=O)=O)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NUWXTOULZJWJQP-UHFFFAOYSA-N 0.000 claims 1
- PZQITBYEBDBEHZ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-(3,4-dihydroxypiperidin-1-yl)-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(O)C(O)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PZQITBYEBDBEHZ-UHFFFAOYSA-N 0.000 claims 1
- GPELJVJUCNKSTJ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-(4-ethylsulfonylpiperazin-1-yl)-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 GPELJVJUCNKSTJ-UHFFFAOYSA-N 0.000 claims 1
- QAMDIXUNDZYWDA-RPWUZVMVSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(2r,3s)-3-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methoxyphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound COC1=CC=CC=C1C1=CC(N2[C@@H]([C@@H](O)CC2)CO)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QAMDIXUNDZYWDA-RPWUZVMVSA-N 0.000 claims 1
- QVLNSHWBAPBCCO-RPWUZVMVSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(2r,3s)-3-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-4-phenylpyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H]([C@@H](O)CC2)CO)C=C(C=2C=CC=CC=2)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QVLNSHWBAPBCCO-RPWUZVMVSA-N 0.000 claims 1
- NVEDVPCTXLXXOM-NRFANRHFSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(2s)-2-(hydroxymethyl)-4-oxopyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CC(=O)C2)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NVEDVPCTXLXXOM-NRFANRHFSA-N 0.000 claims 1
- OXHLQURXAMWJTP-NRFANRHFSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylpyridin-3-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=NC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OXHLQURXAMWJTP-NRFANRHFSA-N 0.000 claims 1
- PUTJEPHVYPNVKP-QFIPXVFZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-4-phenylpyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C=CC=CC=2)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PUTJEPHVYPNVKP-QFIPXVFZSA-N 0.000 claims 1
- NPWZMZCJPQEBML-QFIPXVFZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(2s)-2-formylpyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)C=O)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NPWZMZCJPQEBML-QFIPXVFZSA-N 0.000 claims 1
- AMEKUYJZYIOJEI-DEOSSOPVSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(2s)-4-ethyl-2-(hydroxymethyl)piperazin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound OC[C@@H]1CN(CC)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 AMEKUYJZYIOJEI-DEOSSOPVSA-N 0.000 claims 1
- ZRJVQYCPAHSGSP-VXKWHMMOSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(2s,4s)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@H](O)C2)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZRJVQYCPAHSGSP-VXKWHMMOSA-N 0.000 claims 1
- SLMVSRHIEKEKQZ-FGZHOGPDSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(3r,5r)-3,5-dihydroxypiperidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@H](O)C[C@@H](O)C2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SLMVSRHIEKEKQZ-FGZHOGPDSA-N 0.000 claims 1
- HCAFEIHDCWOFTO-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[2-(hydroxymethyl)morpholin-4-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(CO)OCC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HCAFEIHDCWOFTO-UHFFFAOYSA-N 0.000 claims 1
- OIWIQCNKFSJMSU-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[2-hydroxyethyl(methyl)amino]-4-(4-methylpyridin-3-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CCO)C)=CC(C=2C(=CC=NC=2)C)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OIWIQCNKFSJMSU-UHFFFAOYSA-N 0.000 claims 1
- AUGKBNFKZRMWBE-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[4-(chloromethylsulfonyl)piperazin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCN(CC2)S(=O)(=O)CCl)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 AUGKBNFKZRMWBE-UHFFFAOYSA-N 0.000 claims 1
- NHCPBVZIJCQQEP-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[4-(dimethylsulfamoyl)piperazin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1CN(S(=O)(=O)N(C)C)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 NHCPBVZIJCQQEP-UHFFFAOYSA-N 0.000 claims 1
- XULZBUVVAXCHRU-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[4-hydroxy-3-(hydroxymethyl)piperidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CC(CO)C(O)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XULZBUVVAXCHRU-UHFFFAOYSA-N 0.000 claims 1
- XTEDRRLICPYEAP-KRWDZBQOSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[[(2s)-2-hydroxypropyl]amino]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(NC[C@@H](O)C)=CC(C=2C(=CC=CC=2)C)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XTEDRRLICPYEAP-KRWDZBQOSA-N 0.000 claims 1
- KQBYHYKOYTURKH-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[ethyl(2-hydroxyethyl)amino]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CCO)CC)=CC(C=2C(=CC=CC=2)C)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 KQBYHYKOYTURKH-UHFFFAOYSA-N 0.000 claims 1
- MUHSZCUESFBVHE-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[ethyl(2-hydroxyethyl)amino]-4-(4-fluorophenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)(C)C(=O)N(C)C=1C=NC(N(CCO)CC)=CC=1C1=CC=C(F)C=C1 MUHSZCUESFBVHE-UHFFFAOYSA-N 0.000 claims 1
- JRRXDSOJQRAWQI-IBGZPJMESA-N 2-[3-chloro-5-(difluoromethoxy)phenyl]-n-[4-(2-chlorophenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(Cl)=CC(OC(F)F)=C1 JRRXDSOJQRAWQI-IBGZPJMESA-N 0.000 claims 1
- DWUJDKXEYKICRI-QFIPXVFZSA-N 2-[3-fluoro-5-(trifluoromethyl)phenyl]-n-[6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(F)=CC(C(F)(F)F)=C1 DWUJDKXEYKICRI-QFIPXVFZSA-N 0.000 claims 1
- WMYASOOECBTZTN-YHBQERECSA-N CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(N[C@H]2CC[C@H](O)CC2)cc1-c1ccc(F)cc1C Chemical compound CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(N[C@H]2CC[C@H](O)CC2)cc1-c1ccc(F)cc1C WMYASOOECBTZTN-YHBQERECSA-N 0.000 claims 1
- FFJBUORBJPZAQP-MEMLXQNLSA-N CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(N[C@H]2CC[C@H](O)CC2)cc1-c1ccccc1Br Chemical compound CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(N[C@H]2CC[C@H](O)CC2)cc1-c1ccccc1Br FFJBUORBJPZAQP-MEMLXQNLSA-N 0.000 claims 1
- 102100037346 Substance-P receptor Human genes 0.000 claims 1
- DNCOXMOSAZRSRA-DEOSSOPVSA-N [(2s)-1-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl]-methylamino]-4-(4-fluoro-2-methylphenyl)pyridin-2-yl]pyrrolidin-2-yl]methyl n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC[C@@H]1CCCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 DNCOXMOSAZRSRA-DEOSSOPVSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- YQRAQQAFOPHBPF-FQEVSTJZSA-N n-[4-(2-chlorophenyl)-6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(F)=CC(C(F)(F)F)=C1 YQRAQQAFOPHBPF-FQEVSTJZSA-N 0.000 claims 1
- JURLAYIQAMGEGT-VQTJNVASSA-N n-[4-(2-chlorophenyl)-6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-2-(3,5-dichlorophenyl)-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(Cl)=CC(Cl)=C1 JURLAYIQAMGEGT-VQTJNVASSA-N 0.000 claims 1
- OZTVGBAMACWEEQ-FCHUYYIVSA-N n-[4-(2-chlorophenyl)-6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-2-(3,5-dimethylphenyl)-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C)=CC(C)=C1 OZTVGBAMACWEEQ-FCHUYYIVSA-N 0.000 claims 1
- IYDINJULEHVTIC-UHFFFAOYSA-N n-[6-(3-acetylimidazolidin-1-yl)-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CN(CC2)C(C)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IYDINJULEHVTIC-UHFFFAOYSA-N 0.000 claims 1
- HKJFJUOBEUFJBX-UHFFFAOYSA-N n-[6-(4-acetamidopiperidin-1-yl)-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCC(CC2)NC(C)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HKJFJUOBEUFJBX-UHFFFAOYSA-N 0.000 claims 1
- YBGWMVSYTAUHHT-DEOSSOPVSA-N n-[6-[(2s)-2-(acetamidomethyl)pyrrolidin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CNC(C)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YBGWMVSYTAUHHT-DEOSSOPVSA-N 0.000 claims 1
- PKVSTVHDVPEHGC-DEOSSOPVSA-N n-[6-[(2s)-4-acetyl-2-(hydroxymethyl)piperazin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CN(CC2)C(C)=O)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PKVSTVHDVPEHGC-DEOSSOPVSA-N 0.000 claims 1
- JXNUEGDJJRMOCI-RUZDIDTESA-N n-[6-[(3r)-3-[acetyl(ethyl)amino]pyrrolidin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C1[C@H](N(CC)C(C)=O)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 JXNUEGDJJRMOCI-RUZDIDTESA-N 0.000 claims 1
- NUYROXFIPCFOKS-XMMPIXPASA-N n-[6-[(3r)-3-[acetyl(methyl)amino]pyrrolidin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C1[C@H](N(C)C(C)=O)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 NUYROXFIPCFOKS-XMMPIXPASA-N 0.000 claims 1
- QKWWAULVFNSHIK-HSZRJFAPSA-N n-[6-[(3r)-3-acetamidopyrrolidin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@@H](CC2)NC(C)=O)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QKWWAULVFNSHIK-HSZRJFAPSA-N 0.000 claims 1
- YBSRFGXNRYVDSU-OAQYLSRUSA-N n-[6-[(3r)-3-aminopyrrolidin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2C[C@H](N)CC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YBSRFGXNRYVDSU-OAQYLSRUSA-N 0.000 claims 1
- NUYROXFIPCFOKS-DEOSSOPVSA-N n-[6-[(3s)-3-[acetyl(methyl)amino]pyrrolidin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C1[C@@H](N(C)C(C)=O)CCN1C1=CC(C=2C(=CC(F)=CC=2)C)=C(N(C)C(=O)C(C)(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=N1 NUYROXFIPCFOKS-DEOSSOPVSA-N 0.000 claims 1
- YOVLBCAJHBBWLN-UHFFFAOYSA-N n-[6-[bis(2-hydroxyethyl)amino]-4-(2-bromophenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N(CCO)CCO)C=C(C=2C(=CC=CC=2)Br)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YOVLBCAJHBBWLN-UHFFFAOYSA-N 0.000 claims 1
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 7
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 208000007415 Anhedonia Diseases 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 101000655188 Homo sapiens Tachykinin-3 Proteins 0.000 description 2
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102100037342 Substance-K receptor Human genes 0.000 description 2
- 102100033009 Tachykinin-3 Human genes 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- NAOZHWNXUHWYLV-UHFFFAOYSA-N n-[6-[bis(2-hydroxyethyl)amino]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N(CCO)CCO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NAOZHWNXUHWYLV-UHFFFAOYSA-N 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 125000006308 propyl amino group Chemical group 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- SJTQSZGHQIIKNU-FCHUYYIVSA-N 2-(3,5-dichlorophenyl)-n-[4-(4-fluoro-2-methylphenyl)-6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(Cl)=CC(Cl)=C1 SJTQSZGHQIIKNU-FCHUYYIVSA-N 0.000 description 1
- AFOMAUBOSUBLQS-QFIPXVFZSA-N 2-(3,5-dichlorophenyl)-n-[6-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CCC2)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(Cl)=CC(Cl)=C1 AFOMAUBOSUBLQS-QFIPXVFZSA-N 0.000 description 1
- CBXPOUVFGBFQDM-FCHUYYIVSA-N 2-(3,5-dichlorophenyl)-n-[6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(Cl)=CC(Cl)=C1 CBXPOUVFGBFQDM-FCHUYYIVSA-N 0.000 description 1
- CJTUMEIDUUCTSL-VQTJNVASSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CJTUMEIDUUCTSL-VQTJNVASSA-N 0.000 description 1
- BJGOQFGYQIOPSP-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[2,3-dihydroxypropyl(methyl)amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CC(O)CO)C)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BJGOQFGYQIOPSP-UHFFFAOYSA-N 0.000 description 1
- VVRKQCXRSANSIV-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-chlorophenyl)-6-[ethyl(2-hydroxyethyl)amino]pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CCO)CC)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VVRKQCXRSANSIV-UHFFFAOYSA-N 0.000 description 1
- HFOMSPUMJMDLAR-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-(1,3-dihydroxypropan-2-ylamino)-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NC(CO)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HFOMSPUMJMDLAR-UHFFFAOYSA-N 0.000 description 1
- CWQSLAKGIUPEGE-YADHBBJMSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[(2s,4r)-4-fluoro-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](F)C2)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CWQSLAKGIUPEGE-YADHBBJMSA-N 0.000 description 1
- DMATVJNTKAIYFB-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[1,3-dihydroxypropan-2-yl(methyl)amino]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(C(CO)CO)C)=CC(C=2C(=CC(F)=CC=2)C)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DMATVJNTKAIYFB-UHFFFAOYSA-N 0.000 description 1
- RLRSXUQRSYHENX-HXUWFJFHSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[[(2r)-2,3-dihydroxypropyl]amino]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NC[C@@H](O)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RLRSXUQRSYHENX-HXUWFJFHSA-N 0.000 description 1
- XTEDRRLICPYEAP-QGZVFWFLSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[[(2r)-2-hydroxypropyl]amino]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C1=NC(NC[C@H](O)C)=CC(C=2C(=CC=CC=2)C)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XTEDRRLICPYEAP-QGZVFWFLSA-N 0.000 description 1
- RLRSXUQRSYHENX-FQEVSTJZSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-[[(2s)-2,3-dihydroxypropyl]amino]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(NC[C@H](O)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RLRSXUQRSYHENX-FQEVSTJZSA-N 0.000 description 1
- BPJJWMBXIBKBKQ-LEWJYISDSA-N 2-[3-chloro-5-(difluoromethoxy)phenyl]-n-[6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(Cl)=CC(OC(F)F)=C1 BPJJWMBXIBKBKQ-LEWJYISDSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010005885 Blunted affect Diseases 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019079 Hallucinations, mixed Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 206010036467 Poverty of speech Diseases 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 108010072901 Tachykinin Receptors Proteins 0.000 description 1
- 102000007124 Tachykinin Receptors Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- DWUSUNYJUPLRBL-FCHUYYIVSA-N n-[4-(4-fluoro-2-methylphenyl)-6-[(2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](C[C@@H](O)C2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(F)=CC(C(F)(F)F)=C1 DWUSUNYJUPLRBL-FCHUYYIVSA-N 0.000 description 1
- RUFGTJUJAQZGFN-UHFFFAOYSA-N n-[6-[bis(2-hydroxyethyl)amino]-4-(4-fluorophenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N(CCO)CCO)C=C(C=2C=CC(F)=CC=2)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RUFGTJUJAQZGFN-UHFFFAOYSA-N 0.000 description 1
- SRKQWOWPKWZRSC-UHFFFAOYSA-N n-[6-[bis(2-hydroxypropyl)amino]-4-(2-chlorophenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CC(C)O)CC(O)C)=CC(C=2C(=CC=CC=2)Cl)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SRKQWOWPKWZRSC-UHFFFAOYSA-N 0.000 description 1
- LFXRVWXLKNIJLX-UHFFFAOYSA-N n-[6-[bis(2-hydroxypropyl)amino]-4-(2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C1=NC(N(CC(C)O)CC(O)C)=CC(C=2C(=CC=CC=2)C)=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LFXRVWXLKNIJLX-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 239000002740 neurokinin 3 receptor antagonist Substances 0.000 description 1
- DZOJBGLFWINFBF-UMSFTDKQSA-N osanetant Chemical compound C([C@](C1)(CCCN2CCC(CC2)(N(C(C)=O)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 DZOJBGLFWINFBF-UMSFTDKQSA-N 0.000 description 1
- 229950009875 osanetant Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 201000000381 schizophrenia 1 Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03014513 | 2003-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200510453B true ZA200510453B (en) | 2007-01-31 |
Family
ID=33560750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200510453A ZA200510453B (en) | 2003-07-03 | 2005-12-22 | Dual NK 1/NK 3 antagonists for treating schizophrenia |
Country Status (27)
Country | Link |
---|---|
US (3) | US20050090533A1 (pt) |
EP (1) | EP1643998B1 (pt) |
JP (1) | JP4490421B2 (pt) |
KR (1) | KR100744859B1 (pt) |
CN (1) | CN1852712B (pt) |
AR (1) | AR044974A1 (pt) |
AT (1) | ATE371451T1 (pt) |
AU (1) | AU2004253267B2 (pt) |
BR (1) | BRPI0412291A (pt) |
CA (1) | CA2530886C (pt) |
CO (1) | CO5650234A2 (pt) |
DE (1) | DE602004008631T2 (pt) |
DK (1) | DK1643998T3 (pt) |
ES (1) | ES2291891T3 (pt) |
HR (1) | HRP20070471T3 (pt) |
IL (1) | IL172614A (pt) |
MX (1) | MXPA06000192A (pt) |
MY (1) | MY137156A (pt) |
NO (1) | NO20056007L (pt) |
NZ (1) | NZ544244A (pt) |
PL (1) | PL1643998T3 (pt) |
PT (1) | PT1643998E (pt) |
RU (1) | RU2347777C2 (pt) |
SI (1) | SI1643998T1 (pt) |
TW (1) | TW200502230A (pt) |
WO (1) | WO2005002577A1 (pt) |
ZA (1) | ZA200510453B (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004034619A1 (de) * | 2004-07-16 | 2006-02-23 | Grünenthal GmbH | Substituierte Aminoverbindungen als 5-HT/NA Uptakehemmer |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
DE102004039789A1 (de) * | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
ES2540966T3 (es) | 2005-02-16 | 2015-07-15 | Anacor Pharmaceuticals, Inc. | Compuestos biocidas de boronoftalida |
ES2329827T3 (es) * | 2005-02-22 | 2009-12-01 | F. Hoffmann-La Roche Ag | Antagonistas de nk1. |
CN101146775B (zh) * | 2005-03-23 | 2012-07-18 | 弗·哈夫曼-拉罗切有限公司 | 用于呕吐的用作nk-i拮抗剂的代谢物 |
WO2006119390A1 (en) * | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
US7880008B2 (en) * | 2005-05-31 | 2011-02-01 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
DK1928886T3 (da) * | 2005-09-09 | 2011-07-11 | Glaxosmithkline Llc | Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser |
GB0518472D0 (en) * | 2005-09-09 | 2005-10-19 | Glaxo Group Ltd | Novel compounds |
WO2007039123A2 (en) * | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
BRPI0621279B1 (pt) | 2005-12-30 | 2021-07-20 | Anacor Pharmaceuticals, Inc | Moléculas pequenas contendo boro |
CN102532180B (zh) * | 2005-12-30 | 2016-06-29 | 安纳考尔医药公司 | 含硼的小分子 |
EP2007726B1 (en) | 2006-02-07 | 2011-03-02 | F. Hoffmann-La Roche AG | Benzamide and heteroarene derivatives as cetp inhibitors |
CA2682506C (en) * | 2007-04-20 | 2016-05-24 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists |
CN101778837A (zh) | 2007-08-07 | 2010-07-14 | 弗·哈夫曼-拉罗切有限公司 | 作为nk3受体拮抗剂的吡咯烷芳基-醚 |
GB0808747D0 (en) * | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
GB0814340D0 (en) | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
CA2772168C (en) * | 2009-08-27 | 2019-01-08 | Glaxosmithkline Llc | Anhydrate forms of a pyridine derivative |
WO2011054773A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Novel lactam compounds |
US20110144081A1 (en) * | 2009-12-15 | 2011-06-16 | Henner Knust | Pyrrolidine derivatives |
US8487102B2 (en) | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
CA2930008A1 (en) * | 2013-11-08 | 2015-05-14 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
CN114306347A (zh) | 2015-05-18 | 2022-04-12 | 康堤医疗有限公司 | 用于治疗性激素依赖性疾病的双重nk-1/nk-3受体拮抗剂 |
HUE049979T2 (hu) | 2017-03-20 | 2020-11-30 | Forma Therapeutics Inc | Pirrolopirrol készítmények piruvát-kináz (PKR) aktivátorokként |
MX2020009438A (es) | 2018-03-14 | 2022-05-11 | Kandy Therapeutics Ltd | Formulacion farmaceutica novedosa que comprende antagonistas del receptor dual nk-1/nk-3. |
BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
CN113226356A (zh) | 2018-09-19 | 2021-08-06 | 福马治疗股份有限公司 | 活化丙酮酸激酶r |
CN114728906B (zh) | 2019-11-15 | 2024-08-20 | 康堤医疗有限公司 | 制备nt-814的关键中间体6-氯-4-(4-氟-2-甲基苯基)吡啶-3-胺的新化学方法 |
EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
SG52217A1 (en) | 1993-12-29 | 1998-09-28 | Merck Sharp & Dohme | Substituted morpholine derivatives and their use as therapeutic agents |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
FR2719311B1 (fr) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
WO1998024445A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating schizophrenic disorders |
US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
WO2000050398A2 (en) | 1999-02-24 | 2000-08-31 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
PT1103545E (pt) | 1999-11-29 | 2004-03-31 | Hoffmann La Roche | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida |
KR100501608B1 (ko) * | 2000-07-14 | 2005-07-18 | 에프. 호프만-라 로슈 아게 | 4-페닐-피리딘 유도체의 nk1 수용체의 길항성선구약물로서의 n-산화물 |
TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
EP1192952A3 (en) | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
KR100599134B1 (ko) * | 2001-04-23 | 2006-07-12 | 에프. 호프만-라 로슈 아게 | 양성 전립선 비대증에 대한 nk-1 수용체 길항물질의 용도 |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
-
2004
- 2004-06-25 NZ NZ544244A patent/NZ544244A/xx unknown
- 2004-06-25 WO PCT/EP2004/006929 patent/WO2005002577A1/en active IP Right Grant
- 2004-06-25 AU AU2004253267A patent/AU2004253267B2/en not_active Ceased
- 2004-06-25 PT PT04740337T patent/PT1643998E/pt unknown
- 2004-06-25 DE DE602004008631T patent/DE602004008631T2/de not_active Expired - Lifetime
- 2004-06-25 JP JP2006518043A patent/JP4490421B2/ja not_active Expired - Fee Related
- 2004-06-25 BR BRPI0412291-7A patent/BRPI0412291A/pt not_active Application Discontinuation
- 2004-06-25 DK DK04740337T patent/DK1643998T3/da active
- 2004-06-25 CA CA2530886A patent/CA2530886C/en not_active Expired - Fee Related
- 2004-06-25 ES ES04740337T patent/ES2291891T3/es not_active Expired - Lifetime
- 2004-06-25 KR KR1020067000167A patent/KR100744859B1/ko not_active IP Right Cessation
- 2004-06-25 EP EP04740337A patent/EP1643998B1/en not_active Expired - Lifetime
- 2004-06-25 AT AT04740337T patent/ATE371451T1/de active
- 2004-06-25 PL PL04740337T patent/PL1643998T3/pl unknown
- 2004-06-25 CN CN2004800253601A patent/CN1852712B/zh not_active Expired - Fee Related
- 2004-06-25 SI SI200430471T patent/SI1643998T1/sl unknown
- 2004-06-25 RU RU2006103010/04A patent/RU2347777C2/ru not_active IP Right Cessation
- 2004-06-25 MX MXPA06000192A patent/MXPA06000192A/es active IP Right Grant
- 2004-06-30 TW TW093119675A patent/TW200502230A/zh unknown
- 2004-07-01 AR ARP040102313A patent/AR044974A1/es not_active Application Discontinuation
- 2004-07-02 MY MYPI20042647A patent/MY137156A/en unknown
- 2004-07-02 US US10/884,707 patent/US20050090533A1/en not_active Abandoned
-
2005
- 2005-12-15 IL IL172614A patent/IL172614A/en not_active IP Right Cessation
- 2005-12-16 NO NO20056007A patent/NO20056007L/no not_active Application Discontinuation
- 2005-12-22 ZA ZA200510453A patent/ZA200510453B/en unknown
- 2005-12-29 CO CO05131296A patent/CO5650234A2/es not_active Application Discontinuation
-
2007
- 2007-10-10 HR HR20070471T patent/HRP20070471T3/xx unknown
-
2009
- 2009-01-29 US US12/361,569 patent/US7939533B2/en not_active Expired - Fee Related
-
2011
- 2011-03-31 US US13/076,891 patent/US8404708B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200510453B (en) | Dual NK 1/NK 3 antagonists for treating schizophrenia | |
US20200325130A1 (en) | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | |
JP2020050682A (ja) | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 | |
US20130310340A1 (en) | Method of treating muscular degradation | |
CN111601593B (zh) | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd | |
TWI780329B (zh) | 經1,3-噻唑-2-基取代之苯甲醯胺用於治療與神經纖維敏化作用相關疾病之用途 | |
RU2015131314A (ru) | 3-замещенные пиразолы и их применение в качестве ингибиторов dlk | |
US20180092916A1 (en) | Methods of treating disease-induced ataxia and non-ataxic imbalance | |
US20220218700A1 (en) | Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea | |
KR20170029427A (ko) | 자가면역 질환의 치료 | |
JP2020511486A (ja) | イソオキサゾールカルボキサミド化合物及びその使用 | |
WO2021170811A1 (en) | Method of treating eye disease using trpv4 antagonists | |
CN114748622B (zh) | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd |